Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life

Pulmonary Pharmacology and Therapeutics - Tập 61 - Trang 101899 - 2020
Bruno Sposato1,2, Gianna Camiciottoli3, Elena Bacci4, Marco Scalese5, Giovanna Elisiana Carpagnano6, Corrado Pelaia7, Pierachille Santus8, Mauro Maniscalco9, Simonetta Masieri10, Angelo Corsico11, Nicola Scichilone12, Stefano Baglioni13, Nicola Murgia14, Ilenia Folletti15, Giulio Bardi16, Amelia Grosso11, Paolo Cameli17, Manuela Latorre4, Antonino Musarra18, Elena Bargagli17
1Azienda USL Toscana Sud-Est Pneumology Department, “Misericordia” Hospital, Grosseto, Italy
2Experimental Medicine and Systems, “PhD Program” Department of Systems Medicine University of Rome “Tor Vergata”, Italy
3Section of Respiratory Medicine, Department of Experimental and Clinical Medicine, Careggi University Hospital, University of Florence, Largo A Brambilla 3, 50134, Florence, Italy
4Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Pisa, Italy
5Clinic Physiology Institute, National Research Centre, Pisa, Italy
6Institute of Respiratory Diseases, Department of Medical and Surgical Sciences, University of Foggia, Italy
7Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia” of Catanzaro, Catanzaro, Italy
8Department of Biomedical and Clinical Sciences (DIBIC), Università Degli Studi di Milano, Division of Pulmonary Diseases, Ospedale L. Sacco, ASST Fatebenfratelli-Sacco, Milan, Italy
9Institute Clinic Scientific Maugeri IRCCS, Respiratory Rehabilitation of the Institute of Telese, 82037, Telese Terme, BN, Italy
10Department of Sense Organs, Otorhinolaryngology Clinic, Policlinico Umberto I, “Sapienza” University, Rome, Italy
11Division of Respiratory Diseases, IRCCS “San Matteo” Hospital Foundation, University of Pavia, Italy
12Biomedical Department of Internal Medicine and Medical Specialties (DIBIMIS), University of Palermo, Palermo, Italy
13Pneumology Department, Perugia Hospital, Italy
14Section of Occupational Medicine, Respiratory Diseases and Toxicology, University of Perugia, Perugia, Italy
15Occupational Medicine, Terni Hospital, University of Perugia, Perugia, Italy
16Internal Medicine Department, Azienda USL 6 Livorno, Piombino Hospital, Italy
17Department of Medicine, Surgery and Neurosciences, Respiratory Diseases and Lung Transplant Unit, University of Siena, Siena, Italy
18Allergology Department, Casa della Salute di Scilla, Scilla, RC, Italy

Tài liệu tham khảo

Chung, 2014, International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma, Eur. Respir. J., 43, 343, 10.1183/09031936.00202013 Vianello, 2019, Prevalence of severe asthma according to the drug regulatory agency perspective: an Italian experience, World Allergy Organ. J., 12, 100032, 10.1016/j.waojou.2019.100032 Nunes, 2017, Asthma costs and social impact, Asthma Res. Pract., 3, 1, 10.1186/s40733-016-0029-3 Settipane, 2019, Evaluating direct costs and productivity losses of asthma patients receiving GINA 4/5 therapy in the US, Ann. Allergy Asthma Immunol., 123, 564, 10.1016/j.anai.2019.08.462 Comberiati, 2019, Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma, J. Allergy Clin. Immunol. In Pract., 7, 2689, 10.1016/j.jaip.2019.05.053 Global Initiative for Asthma Ortega, 2014, MENSA Investigators, Mepolizumab treatment in patients with severe eosinophilic asthma, N. Engl. J. Med., 371, 1198, 10.1056/NEJMoa1403290 Pavord, 2012, Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial, Lancet, 380, 651, 10.1016/S0140-6736(12)60988-X Bel, 2014, SIRIUS Investigators, Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma, N. Engl. J. Med., 371, 1189, 10.1056/NEJMoa1403291 Lugogo, 2016, Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study, Clin. Therapeut., 38, 2058, 10.1016/j.clinthera.2016.07.010 Drick, 2018, Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response, BMC Pulm. Med., 18, 119, 10.1186/s12890-018-0689-2 Kurosawa, 2019, Prospective open-label study of 48-week subcutaneous administration of mepolizumab in Japanese patients with severe eosinophilic asthma, J Investig. Allergol. Clin. Immunol., 29, 40, 10.18176/jiaci.0285 Bagnasco, 2018, The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials, World Allergy Organ. J., 11, 34, 10.1186/s40413-018-0210-7 Bagnasco, 2019, One year of mepolizumab. Efficacy and safety in real-life in Italy, Pulm. Pharmacol. Therapeut., 58, 101836, 10.1016/j.pupt.2019.101836 Pelaia, 2018, Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study, Pulm. Pharmacol. Therapeut., 53, 1, 10.1016/j.pupt.2018.09.006 Pertzov, 2019, Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma, J. Asthma, 1, 10.1080/02770903.2019.1658208 Konstantinos Katsoulis, 2016, Techniques for assessing small airways function: possible applications in asthma and COPD, Respir. Med., 119, e2, 10.1016/j.rmed.2013.05.003 Siroux, 2016, Forced midexpiratory flow between 25% and 75% of forced vital capacity is associated with long-term persistence of asthma and poor asthma outcomes, J. Allergy Clin. Immunol., 137, 1709, 10.1016/j.jaci.2015.10.029 Farah, 2019, Mepolizumab improves small airway function in severe eosinophilic asthma, Respir. Med., 148, 49, 10.1016/j.rmed.2019.01.016 Schatz, 2009, The minimally important difference of the Asthma Control Test, J. Allergy Clin. Immunol., 124, 719, 10.1016/j.jaci.2009.06.053 Carr, 2018, Eosinophilic and noneosinophilic asthma, Am. J. Respir. Crit. Care Med., 197, 22, 10.1164/rccm.201611-2232PP Bakakos, 2019, Severe eosinophilic asthma, J. Clin. Med., 8, E1375, 10.3390/jcm8091375 Ciółkowski, 2019, Eosinophilic airway inflammation is a main feature of unstable asthma in adolescents, Respir. Med., 147, 7, 10.1016/j.rmed.2018.12.009 Sposato, 2019, Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes, J. Allergy Clin. Immunol. In Pract., 7, 1643, 10.1016/j.jaip.2019.03.006 Pavord, 2019, Oral corticosteroid-dependent asthma: current knowledge and future needs, Curr. Opin. Pulm. Med., 25, 51, 10.1097/MCP.0000000000000541 Sposato, 2017, Xolair Italian Study Group, Can the response to Omalizumab be influenced by treatment duration? A real-life study, Pulm. Pharmacol. Therapeut., 44, 38, 10.1016/j.pupt.2017.03.004 McQueen, 2018, Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations, Pharmacoeconomics, 36, 957, 10.1007/s40273-018-0658-x Albers, 2019, Update: mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use, Allergy, Sep 14 Chapman, 2019, The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma, Allergy, 74, 1716, 10.1111/all.13850 Magnan, 2016, Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment, Allergy, 71, 1335, 10.1111/all.12914 Bagnasco, 2019, Efficacy of mepolizumab in patients with previous omalizumab treatment failure: real-life observation, Allergy
Thông tin
Thông tin xuất bản

Pulmonary Pharmacology and Therapeutics

Tập 61

101899

Thông tin tác giả